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hematologic recovery was observed in most patients, with values of
ANC 	500 and platelet 	20,000 being reached at 13 and 16 days,
respectively. Cardiac toxicity was monitored by echocardiogram.
All patients demonstrated a normal left ventricular ejection frac-
tion (LVEF) prior to receiving the conditioning regimen. There
were no deaths attributable to heart failure. A signiﬁcant decline in
LVEF developed in only one patient who was over age 60 with
underlying diabetes and hypertension. Ninety-four percent of pa-
tients survived the ﬁrst 100 days following transplant. To date, 7
patients are alive and in remission at 2 to 7 years since disease
onset, with no patients lost to follow-up. The 3-year failure-free
and overall survival are 44% and 55%, respectively. We conclude
that high dose mitoxantrone and melphalan is an effective and
easily administered conditioning regimen with a low risk of signif-
icant cardiac toxicity despite prior treatment with anthracycline
based chemotherapy, and thus is a safe regimen for APBSCT in
adults with AML.
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5. Hematology Oncology Unit, Catholic University, Campobasso, Italy.
High dose therapy plus Autologous Stem Cell Transplantation
(ASCT) is a milestone treatment program for most hematologic
malignancies. ASCO guidelines recommend the use of granulocyte
colony stimulating factors (G-CSF) in the post-infusion phase, to
shorten the period of severe neutropenia and reduce the related
risk of life-threatening infections. Thus, daily subcutaneous injec-
tions of G-CSF (ﬁlgrastim/lenograstim) at 5 g/kg dose until
ANC 	 500/l are routinely administered from day 1 following
ASCT, in order to accelerate hematopoietic recovery and to avoid
neutropenic complications. Pegﬁlgrastim, a novel long-acting re-
combinant G-CSF, has been shown to have similar efﬁcacy when
compared to G-CSF for chemotherapy-induced neutropenia, but
little is known about its use in the ASCT setting. We used a 6 mg
ﬁxed dose Pegﬁlgrastim on day 4 following ASCT in 47 patients
(23 male/24 female; median age 56 years; range 22–70 years) with
multiple myeloma (26 pts) and relapsed or refractory Hodgkin’s
and non- Hodgkin’s lymphoma (21 pts). Patients received periph-
eral CD34 stem cells (median number 4.4  106/kg; range 1.8–
1.8) harvested after mobilizing chemotherapy (cytoxan, vinorel-
bine/cytoxan, R-IEV, IGEV, R-ICE) and G-CSF. Standard
conditioning regimens (HD-Melphalan or BEAM) were used. En-
graftment results were compared to those from a historical control
group of 182 patients (median age 56 years; range 16–74 years)
who had received HD-Melphalan or BEAM and ASCT (median
CD34 cells 7.6  106/kg; range 1.8–14.6) supported by G-CSF
(5 g/kg/day from day 1 until ANC 	 500/l). Median number
of days to ANC 	 500/l were comparable between the Pegﬁl-
grastim (10, range 8–15) and G-CSF (11, range 7–22) groups, as
well as the median number of days to PLT 	 20,000/l (Pegﬁl-
grastim  12, range 9–20 vs G-CSF  12, range 7–29). Overall
infectious rates, including FUO and documented infections, were
of 48% and 39% for Pegﬁlgrastim and G-CSF groups, respectively
(P  NS). Median number of days on iv antibiotics were 0 (range
0–18) and 6 (range 0–13) for the Pegﬁlgrastim and G-CSF groups,
respectively. No signiﬁcant differences in the incidence of bone
pain, intensity of transfusion support, and length of hospital stay
were documented between the two groups. These data indicate
that a ﬁxed 6 mg single-dose of Pegﬁlgrastim is safe and effective
to accelerate engraftment after ASCT. No signiﬁcant differences
with G-CSF were apparent as to engraftment times and overall
infectious complications.
266
PREDICTABILITY OF PRETRANSPLANT INTRAVENOUS BUSULFAN
(IVBU) PK DATA IN ACHIEVING TARGETED IVBU AUC’S DURING CON-
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Mookerjee, B.1, Shaw, L.M.2, Tedesco, N.1, Tran, H.3, Wagner, J.L.1,
Flomenberg, N.1 1. Thomas Jefferson University, Philadelphia, PA; 2.
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Eight adult patients with hematological malignancies were enrolled
in a phase I IVBU dose-escalation trial in autologous BMT condi-
tioning. All patients received four daily doses of IVBU followed by 2
days of cyclophosphamide (CP) with amifostine cytoprotection.
There were 4 planned cohorts of patients with an increasing targeted
IVBU AUC of 20% in each subsequent cohort. The targeted average
daily AUC range for IVBU in cohort 1 was 4400–5280 uMolmin/
dose (mean 4800), the AUC range commonly achieved by single daily
doses of 3.2 mg/kg/day. PK data from 6 time points over 5 hours was
obtained from an IVBU test dose of 0.4 mg/kg administered to
patients 7 to 21 days prior to conditioning. Test dose data was used to
achieve the targeted IVBU AUC for conditioning doses 1 and 2.
IVBU PK data was also collected around conditioning doses 1 and 3
at 7 points over 20 hours. If the targeted daily AUC range was not
achieved based on the IVBU PK data for dose 1, IVBU doses were
adjusted to correct the AUC during days 3 and 4 IVBU was measured
in plasma samples using a validated gas chromatography method.
Acetaminophen and metronidazole were held during all IVBU ad-
ministration. Fungal prophylaxis was the same during IVBU test and
conditioning doses. Patients received phenytoin for seizure prophy-
laxis. All PK data followed expected pharmacokinetic behavior. In
cohort no. 1, test dose PK data resulted in achieving the targeted
AUC for 3 of 5 (60%), but in none of the 3 patients in cohort no. #2
based on ﬁrst IVBU conditioning dose PK results. The test dose PK
data resulted in a lower than targeted AUC in 5 patients. Of these 5
patients, 4 achieved the targeted 4-day AUC after dose adjustments.
Hepatic veno-occlusive disease was diagnosed in 2 patients in cohort
no. 2 after IVBU doses were increased to obtain the targeted mean
4-day AUC. The study was closed. Utilizing PK data based on a small
pretransplant IVBU test dose with limited blood sampling of up to 5
hours did not accurately predict conditioning AUCs, especially when
higher targeted AUCs were desired. PK data from ﬁrst dose IVBU
conditioning dose was more predictive of later IVBU conditioning
AUCs. This suggests that conditions during the test dose as proposed
in this study did not accurately reﬂect those of conditioning and/or
that a higher test dose with more comprehensive blood sampling
might be more predictive in estimating IVBU dose when single daily
busulfan is administered with targeting strategy (Table1).
Table 1. IVBU PK Data
Patient
no.
Desired IVBU
Conditioning
AUC Range
Dose 1
AUC
Dose 3
AUC
Ave 4-Day
Daily AUC
1 4400–5280 3558 8590 6074
2 4400–5280 4864 4853 4858
3 4400–5280 5152 6232 5692
4 4400–5280 4771 4870 4820
5 4400–5280 4223 5358 4790
6 5281–6340 4034 6858 5446
7 5281–6340 4905 6586 5745
8 5281–6340 4051 6207 5129
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TANDEM HIGH DOSE THERAPY WITH HEMATOPOIETIC PROGENITOR
CELL RESCUE IN CHILDREN WITH HIGH-RISK SOLID TUMORS
Schneiderman, J.1, Hewlett, B.1, Morgan, E.1, Walterhouse, D.O.1,
Jacobsohn, D.1, Kletzel, M.1 Children’s Memorial Hospital, Chicago, IL.
A major advance in the treatment of high-risk patients with solid
tumors has been to intensify therapy. We hypothesize that the use
of tandem high dose chemotherapy followed by stem cell rescue
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will improve survival in children with high-risk solid tumors. Fif-
teen patients were enrolled from March 2000 to August 2004 with
a median age of 6 years (2–19). Each had received at least 2 courses
of chemotherapy prior to study enrollment. Patients (Table 1) had
the following diagnoses: recurrent Wilms tumor (n  5), high-risk
Ewing’s sarcoma (n  3), recurrent hepatoblastoma (n  2), re-
current retinoblastoma (n  2), recurrent germ cell tumor (n  2),
and undifferentiated sarcoma (n  1). Patients were prepared with
etoposide (800 mg/m2/day on 6, 5, 4), carboplatin (667 mg/
m2/day on 6, 5, 4), and cyclophosphamide (1800 mg/m2/day
on 3, 2) prior to the ﬁrst transplant, and melphalan (60 mg/
m2/day on8,7,6) and cyclophosphamide (500 mg/m2/day on
5, 4, 3, 2) prior to the second. Children received a median
of 3.86  108 TNC/Kg (2.3–9.4) prior to the ﬁrst transplant, and
4.1  108 (2.5–10.5) TNC/Kg prior to the second. Eight patients
were in complete remission and 7 were in partial remission at the
time of ﬁrst transplant. One patient received local radiation instead
of the second transplant due to parental preference. Following each
rescue, patients achieved an ANC 	 500 at a median of 13 days
(11–34) and 12 days (10–31), respectively. Patients achieved a
platelet count 	20,000 at a median of 22 days (13–37) and 37 days
(15–113), respectively. There was a median of 38 days between
rescues (29–49). Five patients received radiation therapy post-
transplant to relapse sites. There were no toxic deaths. Toxicity was
primarily hematopoietic. Nine of 15 are surviving, 2 with recurrent
disease following tandem therapy at a median follow-up of 22 months
(11–55). Relapses following transplant occurred at the primary site
(n  3), distant (n  3), and primary/distant (n  2). Five have died
from progressive disease; 1 from late pulmonary toxicity. We con-
clude that tandem stem cell transplant used as consolidation in pa-
tients with solid tumors is feasible, well tolerated, and offers the
potential for cure in some patients with high-risk disease (Table1).
Table 1. Patient Characteristics
Patient Diagnosis
Stage/
Location
Relapse
Site Prior
to SCT
Relapse Site
Following
SCT
Follow-up
Post
Transplant
1 Undifferentiated
sarcoma
Pelvis NED,
55 months
2 Ewing’s Pelvis Primary
site, lungs
PD, died -
39 months
3 Hepatoblastoma Stage IV Primary site Alive, stable
disease -
53 months
4 Wilms Recurrent
stage IV
Primary site,
lungs
NED,
45 months
5 Ewing’s Pelvis Primary
site, lungs
PD, died -
11 months
6 Wilms Recurrent
stage I
Liver NED,
49 months
7 Wilms Recurrent
stage III
Lungs CNS Alive, stable
disease -
38 months
8 Ewing’s Metastatic NED,
41 months
9 Hepatoblastoma Recurrent
stage IV
Primary site Lungs PD, died -
22 months
10 Germ cell
tumor
Stage IV Pulmonary
toxicity,
died -
19 months
11 Wilms Recurrent
stage II
Primary site Primary
site
NED,
27 months
12 Wilms Recurrent
stage III
Primary site Primary
site
PD, died -
12 months
13 Retinoblastoma Bilateral Sinus, orbit NED,
16 months
14 Retinoblastoma Bilateral Pineal Pineal PD, died -
11 months
15 Germ cell
tumor
Pineal Primary site NED,
13 months
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PHARMACOKINETICS (PK) OF 2 DOSING REGIMENS OF PALIFERMIN IN
PATIENTS (Pts) WITH HEMATOLOGIC MALIGNANCIES (HM) UNDER-
GOING HIGH-DOSE CHEMORADIOTHERAPY AND HEMATOPOIETIC
STEM CELL TRANSPLANTATION (HSCT)
Zia-Amirhosseini, P.1, Salﬁ, M.1, Elhardt, D.1, Aycock, J.1,
Cheah, T.C.1, Cesano, A.1, Hurd, D.D.2 1. Amgen Inc, Thousand Oaks,
CA; 2Wake Forest University School of Medicine, Winsto-Salem, NC.
For patients (pts) with HM undergoing HSCT, oral mucositis
(OM) is a frequent and debilitating complication that negatively
impacts treatment outcomes, patient quality of life, and healthcare
resources. Palifermin reduces the incidence and duration of severe
OM in the HSCT setting. This phase 1 open-label study assessed
the PK of 2 palifermin dosing regimens. Methods: Pts were 18 to
76 years old with HM and a Karnofsky performance score 70%.
Palifermin was administered intravenously once daily as follows: 60
mcg/kg/day for 3 consecutive days on day 11, day 10, and day
9 before conditioning (total body irradiation [TBI]  etopo-
side  cyclophosphamide) and following HSCT on days 0, 1, and
2 (part A) and a single dose of 180 mcg/kg (part B) before condi-
tioning on day 11 and after HSCT on d 0. In part A (6 total
doses), PK parameters were assessed after the ﬁrst, third, fourth,
and sixth doses. In part B (2 total doses), assessments were made
after each dose administration (day 11 and day 0). Results: In
part A, 13 pts received palifermin; in part B, 12 pts received the
single dose on day 11 and 11 pts received the single dose on day
0. For both dosing regimens, palifermin concentrations declined
rapidly (98% decrease) in the ﬁrst 30 minutes postdose, followed
by a slight increase in mean concentrations between 1 and 4 hours
and then a terminal decay phase. Respective mean (SD) PK pa-
rameter values for the 2 dosing regimens are shown in Table 1. In
part A, mean AUC0-t values were comparable between doses 1 and
3 (within 15%) and 1 and 4 (within 1%). In part B, mean PK
parameter values were similar (within 10% of each other) between
doses 1 and 2. The mean AUC after the ﬁrst 180 mcg/kg dose in
part B was approximately 4-fold higher than that after the ﬁrst 60
mcg/kg dose in part A. Mean half-life values ranged between 3.3 to
5.7 hours in part A and the value was 5.4 hours in part B. Con-
clusions:The PK data in pts receiving HSCT were consistent with
approximately dose-linear PK in the dose range of 60 and 180
mcg/kg, with no observed accumulation, based on AUC, after 3
daily doses of 60 mcg/kg in this pt population in the HSCT setting
(Table1).
Table 1.
Dosing
Regimen
(Dosing Day) n
AUC0-t
(hr  ng/mL)
Mean (SD)
Clearance
(mL/hr/kg)
Mean (SD)
Vss (mL/kg)
Mean (SD)
Part A - 60 mcg/kg/day  3 consecutive days
1st dose (day 11) 9 to 13 34.3 (15.9) 1730a (497) 5320a (2330)
3rd dose (day 9) 13 39.8 (36.4) - -
4th dose (day 0) 11 to 13 34.8 (22.5) 2030a (862) 3870a (2080)
6th dose (day 2) 13 21.2 (15.1) - -
Part B - 180 mcg/kg/day  1 day
1st dose (day 11) 12 140 (50.9) 1460 (600) 4290 (3270)
2nd dose (day 0) 11 143 (71.8) 1770 (1290) 4270 (4700)
Accurate computations of clearance (CL) and volume of distribu-
tion at steady state (Vss) were not possible for some concentra-
tion-time proﬁles.
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THE FAILURE OF PROGNOSTIC MODELS (PM) FOR HODGKINS DISEASE
(HD) TO PREDICT OUTCOMES AFTER AUTOLOGOUS STEM CELL
TRANSPLANTATION (ASCT)
Leis, J.F.1, Hansen, K.S.2, Curtin, P.T.1, Hayes-Lattin, B.1,
Lanier, K.S.2, Gruenberg, D.2, Mauro, M.J.1, Segal, G.M.2,
Menashe, J.I.2, Kovacsovics, T.J.1, Simic, A.1, Maziarz, R.T.1 1.
OHSU Cancer Institute, Center for Hematologic Malignancies, Port-
land, OR; 2. Northwest Marrow Transplant Program, Portland, OR.
PM have been developed for patients with advanced HD in an
effort to identify high-risk individuals for and predict outcomes of
ASCT. Four PM were evaluated in patients transplanted in our
program between 1993 and 2005. One hundred and thirteen pa-
tients with relapsed or refractory HD received ASCT. Forty-ﬁve
patients received a conditioning regimen of busulfan, melphalan,
and thiotepa (BuMelTT), whereas 68 patients received other stan-
dard conditioning regimens (SCR) including Cy/TBI/VP (23),
CBV (39), and other (6). Followup is 113 weeks for BuMelTT
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